Liberia - along with Guinea and Sierra Leone - has been hit hard by the Ebola outbreak
Liberian
President Ellen Johnson Sirleaf has lifted the state of emergency
imposed to control an Ebola outbreak that has ravaged the country.
She said the move did not mean "the fight is over", although numbers of new infections were no longer increasing.
The confirmed death toll from the virus is now 5,160 people, almost all of them from Liberia, Guinea and Sierra Leone.
Meanwhile, clinical trials to find an effective treatment for Ebola are due to start in West Africa next month.
The medical charity Medicins Sans Frontieres (MSF), which has
been helping lead the fight against the virus, says three of its
treatment centres will host three separate research projects.
'New hotspots'
In nationwide address, President Johnson Sirleaf said that
night curfews would be reduced and weekly markets could take place
across Liberia.
She added that preparations were being made for the re-opening of schools.
The state of emergency imposed in August had allowed the
local authorities to curb movement in the worst-hit areas of the
country, including the capital Monrovia.
The lifting of the emergency comes after the World Health
Organization (WHO) said "there is some evidence that case incidence is
no longer increasing nationally in Guinea and Liberia".
However, some reports suggest that new fresh hotspots have emerged in Liberia, the Associated Press reports.
'Hope for patients'
In a separate development, MSF announced the new clinical trials: two in Guinea and another one in an unconfirmed location.
One trial will involve using the blood of recovered Ebola patients to treat sick people in the Guinean capital Conakry.
"This is an unprecedented international partnership which
represents hope for patients to finally get a real treatment," said MSF
spokeswoman Dr Annick Antierens.
About 400 people will take part in the trials, and they will
be extended to other centres if the early results - expected in February
2015 - are promising.
The WHO announced in September that experimental treatments and vaccines for Ebola should be fast-tracked.
Two experimental vaccines, produced by GlaxoSmithKline (GSK)
and the Public Health Agency of Canada, have already been fast-tracked
into safety trials.
The GSK vaccine is being tested in Mali, the UK and the US. Research on the Canadian vaccine is also under way in the US.
Cumulative deaths up to 11 November
*Figures are occasionally revised down as suspect or
probable cases are found to be unrelated to Ebola. Figures for Liberia,
Sierra Leone and Guinea up to 9 November, while those for Mali, Nigeria
and the US up to 11 November.